Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma

Previous analyses examining the relationship between blood eosinophil count and mepolizumab treatment effects in severe eosinophilic asthma have used a range of doses and administration routes. This post hoc meta-analysis included data from the MENSA (MEA115588/NCT01691521) and MUSCA (200862/NCT0228...

Full description

Saved in:
Bibliographic Details
Published in:Respiratory medicine 2019-11, Vol.159 (C), p.105806-105806, Article 105806
Main Authors: Albers, Frank C., Licskai, Christopher, Chanez, Pascal, Bratton, Daniel J., Bradford, Eric S., Yancey, Steven W., Kwon, Namhee, Quirce, Santiago
Format: Article
Language:English
Subjects:
Asthma
Blood
Blood eosinophil
Clinical trials
Cytokines
Data analysis
Emergency medical care
Emergency medical services
Exacerbation
Human health and pathology
Leukocytes (eosinophilic)
Licenses
Life Sciences
Lung function
Mepolizumab
Meta-analysis
Monoclonal antibodies
Patients
Predictor
Questionnaires
Subgroups
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Previous analyses examining the relationship between blood eosinophil count and mepolizumab treatment effects in severe eosinophilic asthma have used a range of doses and administration routes. This post hoc meta-analysis included data from the MENSA (MEA115588/NCT01691521) and MUSCA (200862/NCT02281318) trials. Patients (≥12 years) with severe eosinophilic asthma who experienced ≥2 exacerbations in the prior year received either mepolizumab 100 mg subcutaneously (SC) or 75 mg intravenously, or placebo plus standard of care every 4 weeks. This meta-analysis reports data from patients receiving the licensed dose of mepolizumab (100 mg SC) or placebo only. The primary endpoint was the annual rate of clinically significant exacerbations; secondary endpoints included rate of exacerbations requiring hospitalization/emergency room (ER) visit, proportion of patients with no clinically significant exacerbations, and changes from baseline in forced expiratory volume in 1 s, Asthma Control Questionnaire-5 and St George's Respiratory Questionnaire scores. Analyses were stratified by baseline blood eosinophil count (
ISSN:0954-6111
1532-3064
DOI:10.1016/j.rmed.2019.105806